Praxis Precision Medicines (PRAX) Competitors $47.27 -1.33 (-2.74%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$47.30 +0.02 (+0.05%) As of 08/7/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. TLX, PCVX, MRUS, CYTK, RNA, ADMA, KRYS, MTSR, ABVX, and ZLABShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), Merus (MRUS), Cytokinetics (CYTK), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Metsera (MTSR), Abivax (ABVX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Telix Pharmaceuticals Vaxcyte Merus Cytokinetics Avidity Biosciences ADMA Biologics Krystal Biotech Metsera Abivax Zai Lab Telix Pharmaceuticals (NASDAQ:TLX) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Do institutionals & insiders believe in TLX or PRAX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TLX or PRAX more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -2,137.48%. Telix Pharmaceuticals' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Praxis Precision Medicines -2,137.48%-60.07%-54.84% Does the media favor TLX or PRAX? In the previous week, Praxis Precision Medicines had 30 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 37 mentions for Praxis Precision Medicines and 7 mentions for Telix Pharmaceuticals. Praxis Precision Medicines' average media sentiment score of 0.35 beat Telix Pharmaceuticals' score of 0.29 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Praxis Precision Medicines 7 Very Positive mention(s) 6 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate TLX or PRAX? Telix Pharmaceuticals presently has a consensus target price of $22.33, indicating a potential upside of 89.59%. Praxis Precision Medicines has a consensus target price of $95.22, indicating a potential upside of 101.44%. Given Praxis Precision Medicines' higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Telix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has better valuation & earnings, TLX or PRAX? Telix Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$783.21M5.09$32.93MN/AN/APraxis Precision Medicines$8.55M116.38-$182.82M-$12.29-3.85 SummaryPraxis Precision Medicines beats Telix Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-3.8517.9729.9425.14Price / Sales116.38262.51398.9486.71Price / CashN/A41.8335.9458.58Price / Book2.467.238.105.59Net Income-$182.82M-$54.43M$3.26B$265.48M7 Day Performance-12.61%0.22%0.68%1.22%1 Month Performance1.09%5.59%2.46%0.39%1 Year Performance-10.68%9.98%27.69%23.47% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines1.6654 of 5 stars$47.27-2.7%$95.22+101.4%-9.1%$1.02B$8.55M-3.85110Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.81B$516.72M0.00N/APCVXVaxcyte2.1107 of 5 stars$35.87-2.1%$136.50+280.5%-57.4%$4.73BN/A-8.99160News CoverageEarnings ReportAnalyst ForecastGap DownMRUSMerus3.0155 of 5 stars$65.59-1.8%$86.40+31.7%+29.4%$4.62B$36.13M-16.0837Positive NewsEarnings ReportAnalyst ForecastCYTKCytokinetics4.1064 of 5 stars$36.63-1.5%$70.92+93.6%-31.2%$4.44B$18.47M-6.92250News CoverageEarnings ReportRNAAvidity Biosciences2.7652 of 5 stars$34.56-4.7%$66.35+92.0%+15.6%$4.37B$10.90M-11.52190Gap DownADMAADMA Biologics4.2961 of 5 stars$18.00-0.1%$27.67+53.7%+46.3%$4.30B$426.45M21.18530Trending NewsEarnings ReportGap DownKRYSKrystal Biotech4.814 of 5 stars$152.91+3.6%$211.33+38.2%-22.1%$4.27B$290.52M36.76210Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMTSRMetseraN/A$39.43-2.6%$55.00+39.5%N/A$4.25BN/A0.0081ABVXAbivax3.476 of 5 stars$66.57+0.1%$80.00+20.2%+521.8%$4.22BN/A0.0061Upcoming EarningsZLABZai Lab2.5632 of 5 stars$38.69+4.1%$54.28+40.3%+104.7%$4.13B$398.99M-15.541,869News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Telix Pharmaceuticals Competitors Vaxcyte Competitors Merus Competitors Cytokinetics Competitors Avidity Biosciences Competitors ADMA Biologics Competitors Krystal Biotech Competitors Metsera Competitors Abivax Competitors Zai Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
